Results 41 to 50 of about 20,079 (290)

Evaluating Treatment Mechanisms of Varenicline: Mediation by Affect and Craving.

Nicotine & Tobacco Research, 2022
INTRODUCTION Negative reinforcement models posit that relapse to cigarette smoking is driven in part by changes in affect and craving during the quit attempt.
S. Tonkin, C. Colder, M. Mahoney, G. Swan, P. Cinciripini, R. Schnoll, T. George, R. Tyndale, Larry W Hawk   +8 more
semanticscholar   +1 more source

A case report on varenicline induced delirium in an alcohol and nicotine dependent patient

Indian Journal of Psychological Medicine, 2015
Varenicline is a smoking cessation agent. Varenicline acts as a partial agonist of α4β2 neuronal nicotinic acetylcholine receptor and prevents nicotine binding to the same.
A Lakshmi Narayan, H S Virupaksha, G Thejaswi, G R Saraswathy, V Madhavan, Murali Thyloth   +5 more
doaj   +1 more source

Effect of Extending the Duration of Prequit Treatment With Varenicline on Smoking Abstinence

JAMA Network Open, 2022
Key Points Question Does extending the duration of prequit treatment with varenicline improve rates of smoking abstinence? Findings In this randomized clinical trial that included 320 adults, the percentage of bioverified continuous 4-week abstinence ...
L. Hawk, S. Tiffany, C. Colder, R. Ashare, Jennifer Wray, R. Tyndale, T. Brandon, M. Mahoney   +7 more
semanticscholar   +1 more source

Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. [PDF]

PLoS ONE, 2016
UNLABELLED:Schizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains.
Robert C Smith, Revital Amiaz, Tian-Mei Si, Lawrence Maayan, Hua Jin, Sylvia Boules, Henry Sershen, Chunbo Li, Juanjuan Ren, Yanhong Liu, Mary Youseff, Abel Lajtha, Alessandro Guidotti, Mark Weiser, John M Davis   +14 more
doaj   +1 more source

ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Cornea, 2021
Supplemental Digital Content is Available in the Text. Purpose: The purpose of this trial was to evaluate the safety and efficacy of OC-01 (varenicline solution), a nicotinic acetylcholine receptor agonist nasal spray, on signs and symptoms of dry eye ...
David L Wirta, G. Torkildsen, Blair Boehmer, D. Hollander, Edward Bendert, Lijuan Zeng, Michael Ackermann, J. Nau   +7 more
semanticscholar   +1 more source

Use of varenicline and nicotine replacement therapy in people with and without general practitioner-recorded dementia: retrospective cohort study of routine electronic medical records

BMJ Open, 2019
Objectives Our primary objective was to estimate smoking prevalence and prescribing rates of varenicline and nicotine replacement therapy (NRT) in people with and without general practitioner (GP)-recorded dementia.
Amy Taylor, Tim Jones, Taha Itani, Richard Martin, Gemma Taylor, Kyla Thomas, Neil Davies   +6 more
doaj   +1 more source

Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial.

JAMA
Importance Electronic cigarette use (vaping) among adolescents and young adults is common. Few treatments have been tested in this population. Objective To evaluate the efficacy of varenicline for nicotine vaping cessation in youth who do not smoke ...
Evins AE, Cather C, Reeder HT, Evohr B, Potter K, Pachas GN, Gray KM, Levy S, Rigotti NA, Iroegbulem V, Dufour J, Casottana K, Costello MA, Gilman JM, Schuster RM.   +14 more
europepmc   +2 more sources

Implementation of a quality improvement project on smoking cessation reduces smoking in a high risk trauma patient population. [PDF]

, 2016
BackgroundCigarette smoking causes about one of every five deaths in the U.S. each year. In 2013 the prevalence of smoking in our institution's trauma population was 26.7 %, well above the national adult average of 18.1 % according to the CDC website. As
Carrens, Karen, Doben, Andrew, Gross, Ronald, Korntner, Samuel, Nahmias, Jeffry, Poola, Shiva   +5 more
core   +1 more source

Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.

American Journal of Psychiatry, 2021
OBJECTIVE Pharmacological treatments that can concomitantly address cigarette smoking and heavy drinking stand to improve health care delivery for these highly prevalent co-occurring conditions.
L. Ray, ReJoyce Green, Craig K. Enders, A. Leventhal, E. Grodin, Gang Li, Aaron C. Lim, E. Hartwell, A. Venegas, Lindsay R Meredith, Steven J. Nieto, S. Shoptaw, Diana Ho, K. Miotto   +13 more
semanticscholar   +1 more source

Varenicline Interactions at the 5-HT3 Receptor Ligand Binding Site are Revealed by 5-HTBP. [PDF]

, 2015
Cys-loop receptors are the site of action of many therapeutic drugs. One of these is the smoking cessation agent varenicline, which has its major therapeutic effects at nicotinic acetylcholine (nACh) receptors but also acts at 5-HT3 receptors.
Lillestol, Reidun K, Lummis, Sarah CR, Price, Kerry L, Ulens, Chris   +3 more
core   +3 more sources